Exploratory study on short-term administration of oral fosravuconazole for tinea pedis

Area of Science:

• Dermatology
• Mycology
• Pharmacology

Background:

• Tinea pedis, or athlete's foot, is a common fungal infection.
• Current treatments have limitations, necessitating novel therapeutic options.

Purpose of the Study:

• To evaluate the clinical efficacy and safety of short-term oral fosravuconazole (F-RVCZ) for treating tinea pedis.
• To compare F-RVCZ with existing antifungal therapies.

Main Methods:

• Oral F-RVCZ (100 mg ravuconazole equivalent) administered once daily for 1 week (interdigital/vesicular) or 4 weeks (hyperkeratotic).
• Efficacy assessed by mycological and clinical outcomes at multiple time points post-treatment.
• Adverse drug reactions (ADRs) were monitored.

Main Results:

• F-RVCZ demonstrated confirmed efficacy at the end of treatment for both tinea pedis types.
• Therapeutic effects showed a time-dependent increase post-treatment.
• All ADRs were expected, with no discontinuations due to serious adverse events.

Conclusions:

• Short-term oral F-RVCZ is an effective and safe treatment for tinea pedis.
• F-RVCZ may offer superior or comparable efficacy to terbinafine and itraconazole.
• This therapy presents a potentially valuable new option for managing athlete's foot.